Monopar Therapeutics (MNPR) Net Income towards Common Stockholders (2017 - 2025)

Monopar Therapeutics (MNPR) has 9 years of Net Income towards Common Stockholders data on file, last reported at -$4.3 million in Q3 2025.

• For the quarter ending Q3 2025, Net Income towards Common Stockholders fell 189.36% year-over-year to -$4.3 million; the trailing twelve-month figure through Dec 2025 stood at -$10.1 million (down 102.75% YoY), and the FY2025 full-year result was -$13.7 million, up 11.45% from the prior year.
• Net Income towards Common Stockholders declined to -$4.3 million in Q3 2025, from -$2.6 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$1.5 million in Q3 2024 to a low of -$13.4 million in Q4 2022.
• A 5-year average of -$3.5 million and a median of -$2.5 million in 2021 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders surged 31.6% in 2024 and sank 189.36% in 2025, its largest moves.
• Tracing MNPR's Net Income towards Common Stockholders over 5 years: stood at -$10.4 million in 2021, then fell by 29.03% to -$13.4 million in 2022, then soared by 85.44% to -$2.0 million in 2023, then gained by 24.47% to -$1.5 million in 2024, then slumped by 189.36% to -$4.3 million in 2025.
• Business Quant data shows MNPR's Net Income towards Common Stockholders at -$4.3 million in Q3 2025, -$2.6 million in Q2 2025, and -$3.2 million in Q1 2025.